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Purpose
Methylphenidate (MP) (Ritalin®, Concerta®) is a drug
commonly used for the treatment of children affected by
attention-deficit hyperactivity disorder (ADHD). Literature
shows some cases of cardiovascular side-effects, including
arrhythmia and sudden death, but we failed to find a
report of associated skeletal-muscle manifestation.
Methods
We describe a case of a 13 yo girl diagnosed with ADHD
since early childhood, in MP use for the past 3 years. She
complained about a mild discomfort of proximal muscles
of the lower limbs and cramps for the previous 3 months.
Routine exams revealed increased aminotransferases levels
(AST 192 UI/L; ALT 222 UI/L), suggesting hepatotoxicity.
New laboratory tests were ordered, showing a CPK level
of 18300 UI/L, AST 393 and ALT 330. The MP use
became intermittent while the investigation was per-
formed. Two weeks later, AST was 80 and ALT 166. A
thorough investigation showed negative viral serology
(HAV, HBV, HCV, HIV, CMV and EBV); negative autoan-
tibodies (FAN, anti-LKM, anti-smooth muscle, anti-TPO
and anti-tireoglobulin); normal hemogram; negative
inflammatory markers (ESR and PCR) and a normal lower
limbs MRI. An ECG revealed an altered antero-septal
repolarization and echocardiogram was normal. Twenty
days after, a new lab evaluation revealed a decreasing level
of CPK (9670). One month after the complete withdrawal
of the MP, the myalgia and cramps were no more present
and CPK levels decreased to 3160mg/dl.
Results
The decreasing levels of the muscle enzymes and clinical
normalization after the drug discontinuation strongly
suggested a cause-effect association.
Conclusion
As the use of MP has increased so much in the past
decade, new side effects have been related to this drug.
This case may be the first in the literature to show the
association of proximal myopathy to it, and the use of
MP may become an uncommon differential diagnosis
for some cases of proximal myopathy in children and
teenagers.
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